Browse News
Filter News
Found 14,802 articles
-
Stream Biomedical Appoints William D. Schwieterman, M.D. as Chief Executive Officer
10/28/2020
Stream Biomedical, Inc., a privately-held company developing novel therapeutics for the treatment of acute stroke and Alzheimer’s disease, announced today that William D. Schwieterman, M.D. has been appointed as Chief Executive Officer. Gary B. Gage, PE, MBA, the company’s founder, continues as Chief Operating Officer.
-
First-Ever Treatment Shown to Reverse Alzheimer’s Earns NeuroEM Therapeutics FDA Breakthrough Device Status
10/28/2020
NeuroEM Therapeutics is poised to deliver a knockout blow to Alzheimer’s disease. The clinical-stage medical device company is pleased to announce FDA Breakthrough Device designation for its bioengineered head device shown to reverse Alzheimer’s memory loss in its pilot study, published last fall in the Journal of Alzheimer’s Disease.
-
Axsome Therapeutics to Report Third Quarter 2020 Financial Results on November 5, 2020
10/28/2020
Axsome to host conference call and webcast on Thursday, November 5, 2020 at 8:00 AM Eastern Time
-
BioArctic's partner Eisai to present latest data on BAN2401 at CTAD conference
10/28/2020
BioArctic AB announced that the company's partner Eisai will conduct four oral presentations related to the drug candidate BAN2401 at the 13th Clinical Trials on Alzheimer's Disease Conference on November 4-7.
-
APRINOIA Announces Approval from NMPA to Initiate Phase 3 Clinical Trial in China for 18F-APN-1607 Tau PET Imaging Tracer for Dementia
10/28/2020
APRINOIA Therapeutics announced that China National Medical Products Administration had approved to initiate Phase 3 clinical trial to evaluate APRINOIA's positron emission tomography imaging tracer, 18F-APN-1607, targeting abnormal tau protein aggregates in brains of patients of cognitive impairment.
-
"White Matter Lesion" Mapping Tool Identifies Early Signs of Dementia
10/27/2020
A new tool for analyzing tissue damage seen on MRI brain scans can detect with more than 70 percent accuracy early signs of cognitive decline, new research shows.
-
EuMentis Therapeutics Inc. Announces Closing of Series A Financing
10/27/2020
Company focused on development of novel drugs with clinically-validated mechanisms for the treatment of neurodevelopmental and neurodegenerative disorders Lead product candidate, EM-036, has demonstrated superior efficacy in preclinical Autism Spectrum Disorders
-
Cognition Therapeutics Appoints Brett P. Monia to its Board of Directors
10/27/2020
Cognition Therapeutics, Inc., a clinical stage neuroscience company developing drugs that treat neurodegenerative disorders by regulating cellular damage response pathways, today announced the appointment of Brett P. Monia, Ph.D. to its board of directors.
-
Ashvattha Therapeutics Selected to Present Virtual Poster at ACR Convergence 2020
10/27/2020
Ashvattha Therapeutics, a clinical-stage biotech company focused on novel hydroxyl dendrimer therapeutics (HDTs) to treat unmet medical needs in oncology, ocular, and inflammatory diseases, today announced results from a preclinical study demonstrating the successful localization of HDs to target sites of inflammation in arthritic tissues at the ACR Convergence 2020, held virtually November 5-9, 2020.
-
New Immunomodulatory Therapeutic Vaccine that Targets Oligomeric Amyloid-β Could be Step Towards Halting Alzheimer’s Disease Progression
10/27/2020
Alzheimer’s disease affects more than 5.8 million Americans at an estimated cost at over $305 billion in 2020 according to the Alzheimer's Association.
-
Olatec Therapeutics Enrolls its First Patients in a Phase 2 Clinical Trial in COVID-19 with its Selective NLRP3 Inhibitor, Oral Dapansutrile
10/27/2020
Olatec Therapeutics LLC announced today that patients are being enrolled in a trial described as: “A Phase 2 Randomized, Double-Blind, Placebo-Controlled Trial of the Safety and Efficacy of Orally Administered Dapansutrile Capsules for the Treatment of Moderate COVID-19 Symptoms and Evidence of Early Cytokine Release Syndrome.”
-
Alzheon Announces Dosing of First Patient in ALZ-801 Phase 2 Biomarker Study in APOE4 Carriers with Early Alzheimer’s Disease
10/27/2020
Alzheon, Inc. announced the initiation of a Phase 2 study evaluating biomarker effects of ALZ-801, an oral treatment blocking formation of neurotoxic soluble amyloid oligomers, in Early AD patients carrying one or two copies of the ε4 allele of the apolipoprotein E gene.
-
PerkinElmer Launches Industry First No-Wash Immunoassay For Phospho Ubiquitin Ser65 to Help Drive Neuroscience Disease and Therapeutics Research Forward
10/26/2020
PerkinElmer, Inc., a global leader committed to innovating for a healthier world, today launched the life science industry’s first no wash Ubiquitin phosphorylation at Serine 65 immunoassay for studying defective mitophagy biological mechanisms that have been broadly associated with diseases such as Parkinson’s and Alzheimer’s
-
Todos Medical Announces Instrument Validation Complete at MOTO+PARA Mobile Lab
10/26/2020
Todos Medical (OTCQB: TOMDF), an in vitro diagnostics company focused on distributing comprehensive solutions for COVID-19 screening and diagnosis, and developing blood tests for the early detection of cancer and Alzheimer’s disease, today announced the completion of the instrument validation in its mobile lab division.
-
Acadia Pharmaceuticals to Present New Scientific Data on Pimavanserin in Neurodegenerative Diseases at the 13th Clinical Trials on Alzheimer's Disease (CTAD) Conference
10/26/2020
Acadia Pharmaceuticals to Present New Scientific Data on Pimavanserin in Neurodegenerative Diseases at the 13 th Clinical Trials on Alzheimer's Disease (CTAD) Conference
-
Vaccinex, Inc. to Present at the Virtual Investor KOL RoundtableLive moderated video webcast discussion between members of management and Key Opinion Leader, Eric Siemers, MD on Tuesday, October 27th at 10:00 a.m. EDT
10/26/2020
Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating cancer and neurodegenerative disease through the inhibition of SEMA4D, announced today that members of management will participate in the Virtual Investor KOL Roundtable on Tuesday, October 27, 2020 at 10:00 AM ET. Participating in the KOL Roundtable discussion will be Maurice Zauderer, Ph.D., President and Chief Executive
-
After discovering promising indicators on the path to the development of Branaplam (LMIO70) for spinal muscular atrophy, Novartis now hopes to repurpose the drug for the treatment of Hungtington’s disease.
-
HFC Raises Over $325K and Connects Over 2000 Supporters for Alzheimer's Awareness During First Virtual Game Show, Hosted by Seth Rogen
10/23/2020
National Alzheimer's Nonprofit Takes Annual Fundraising Virtual With Celebrity-Hosted, 70s-Themed Game Show Featuring Elizabeth Banks, Anna Faris, Jim Gaffigan, Billy Eichner and Craig Robinson.
-
Researchers with Pfizer and IBM developed an artificial intelligence (AI) model that they claim can predict eventual onset of Alzheimer’s disease with 71% accuracy based on a language sample. They published the research today in The Lancet eClinicalMedicine.
-
Todos Medical Announces Distribution Agreement with Adial Pharmaceuticals to Market the FDA, EUA Authorized, Assure/FaStep(R) Point-of-Care Covid-19 Antibody Tests
10/22/2020
Todos Medical (TOMDF) an in vitro diagnostics company focused on distributing comprehensive solutions for COVID-19 screening and diagnosis, and developing blood tests for the early detection of cancer and Alzheimers disease, along with Adial Pharmaceuticals, Inc.